Biocompatibles gets share price boost after bead patent buy
This article was originally published in Clinica
Shares in UK oncology specialist Biocompatibles International reached their highest price in nearly five years after the firm bought patents protecting its bead products. As Clinica went to press, Biocompatibles’ share price had reached 273.50p on the London Stock Exchange during morning trading – the company’s highest value since September 2005.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals